Litcius/Paper detail

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial

Syed A. Hussain, J.F. Lester, Richard A. Jackson, Matthew Gornall, Muneeb Qureshi, Anthony Elliott, Simon J. Crabb, Robert Huddart, Naveen Vasudev, Alison Birtle, Jane Worlding, Nicholas D. James, Omi Parikh, Maria Vilarino-Varela, Roberto Alonzi, Mark Linch, Irbaz Bin Riaz, James W.F. Catto, Thomas Powles, Robert J. Jones

2022White Rose Research Online (University of Leeds, The University of Sheffield, University of York)25 citations

Topics & Concepts

MedicineGemcitabinePlaceboCystectomyNintedanibBladder cancerInternal medicineClinical endpointPopulationOncologyNeoadjuvant therapyUrologyChemotherapyCancerClinical trialBreast cancerPathologyIdiopathic pulmonary fibrosisLungEnvironmental healthAlternative medicineBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesRenal cell carcinoma treatment
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial | Litcius